Skip to content

EBITDA at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$46.5M-40.3%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$19.55M+3.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.62M+2.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

$35.2Mebit+
$28.0KDepreciation Depletion & Amortization
=-$35.13M

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's EBITDA?
Vor Biopharma (VOR) reported EBITDA of -$35.13M in Q1 2026.
How has Vor Biopharma's EBITDA changed year-over-year?
Vor Biopharma's EBITDA decreased by 8.2% year-over-year, from -$32.47M to -$35.13M.
What is the long-term trend for Vor Biopharma's EBITDA?
Over 4 years (2021 to 2025), Vor Biopharma's EBITDA has grown at a 52.8% compound annual growth rate (CAGR), from -$67.61M to -$368.69M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.